Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000683134
Ethics application status
Approved
Date submitted
3/05/2019
Date registered
7/05/2019
Date last updated
27/10/2023
Date data sharing statement initially provided
7/05/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Study of Ketamine for Youth Depression
Scientific title
Study of Ketamine for Youth Depression
Secondary ID [1] 298125 0
None
Universal Trial Number (UTN)
U1111-1232-6927
Trial acronym
SKY-D
Linked study record
n/a

Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder 312656 0
Condition category
Condition code
Mental Health 311152 311152 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention in SKY-D is low-dose ketamine, administered once a week for 4 weeks. All treatments will be administered using subcutaneous injection. The starting dose (Level 1) of ketamine is 0.6mg/kg. Participants with inadequate treatment response will be provided with an increased dose, up to a maximum dose of 0.9mg/kg of ketamine. Those who are unable to tolerate the starting dose will have their dosage reduced for subsequent treatments to a minimum of 0.5mg/kg of ketamine (Level 0). Ability to tolerate dose will be determined based on participant subjective report and objective observations taken over four hours for the first treatment, and two hours for treatments 2, 3 and 4.
Intervention code [1] 314345 0
Treatment: Drugs
Comparator / control treatment
The control treatment in SKY-D is low-dose midazolam, administered once a week for 4 weeks. All treatments will be administered using subcutaneous injection. The starting dose of midazolam is 0.03mg/kg. Participants with inadequate treatment response will be provided with an increased dose, up to a maximum dose of 0.045mg/kg of midazolam. Those who are unable to tolerate the starting dose will have their dosage reduced for subsequent treatments to a minimum of 0.025mg/kg of midazolam.
Control group
Active

Outcomes
Primary outcome [1] 319927 0
The primary outcome is change in depression scores, defined as a reduction in the researcher-rated MADRS at 4 weeks compared with baseline MADRS.
Timepoint [1] 319927 0
Week 4 (Day 28) Follow-up
Secondary outcome [1] 369906 0
Sustained change in the researcher-rated MADRS compared with baseline MADRS
Timepoint [1] 369906 0
Week 8 (Day 56) and Week 26 (Day 182) Follow-ups
Secondary outcome [2] 369907 0
Change in the researcher-rated MADRS at 24 hours after each of the four treatment sessions, compared with the pre-administration MADRS before each session
Timepoint [2] 369907 0
Days 1, 8, 15 and 22.
Secondary outcome [3] 370055 0
Change in self-rated depression symptoms using the self-rated Quick Inventory of Depression Symptomatology (QIDS).
Timepoint [3] 370055 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups
Secondary outcome [4] 370056 0
Remission of depression defined as MADRS score less than or equal to 10.
Timepoint [4] 370056 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups
Secondary outcome [5] 370057 0
Change in suicidal ideation using the self-report Suicidal Ideation Screen (SIS).
Timepoint [5] 370057 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups
Secondary outcome [6] 370058 0
Absence of suicidal thoughts, defined as a MADRS Suicidality Item score of 0.
Timepoint [6] 370058 0
Week 4 (Day 28) And Week 8 (Day 56) Follow-ups
Secondary outcome [7] 370059 0
Absence of a suicide attempt – defined as a score of 0 on the Columbia Suicide Severity Rating Scale (CSSRS) ‘actual attempt’ criterion.
Timepoint [7] 370059 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups
Secondary outcome [8] 370060 0
Researcher-rated response to treatment, defined as a Clinical Global Impression–Improvement (CGI-I) score of less than or equal to 2 (“much” or “very much” improved).
Timepoint [8] 370060 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups.
Secondary outcome [9] 370061 0
Participant-rated response to treatment, defined as a Patient Global Impression – Improvement (PGI-I) score of less than or equal to 2 (“much” or “very much” improved).
Timepoint [9] 370061 0
Week 4 (Day 28) Follow-up.
Secondary outcome [10] 370062 0
Change in anxiety scores using the Generalized Anxiety Disorder 7-item (GAD-7) scale.
Timepoint [10] 370062 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-up.
Secondary outcome [11] 370063 0
Change in quality of life scores using the Assessment of Quality of Life (AQoL-8D).
Timepoint [11] 370063 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups.
Secondary outcome [12] 370064 0
Change in social and occupational functioning using the Social and Occupational Functioning Assessment Scale (SOFAS).
Timepoint [12] 370064 0
Week 4 (Day 28) and Week 8 (Day 56) Follow-ups.
Secondary outcome [13] 370066 0
Exploratory outcome: To assess the safety of low-dose subcutaneous ketamine by analysing changes in cognitive function (Cogstate).
Timepoint [13] 370066 0
Week 4 (Day 28) Follow-up.
Secondary outcome [14] 370067 0
Exploratory outcome: To assess the safety of low-dose subcutaneous ketamine by analysing changes in clinical blood parameters (include Full Blood Examination, Electrolytes, Urea and Creatinine, Liver Function Test, and Thyroid Function Test).
Timepoint [14] 370067 0
Week 4 (Day 28) Follow-up.
Secondary outcome [15] 370068 0
Exploratory outcome: To assess the safety of low-dose subcutaneous ketamine by analysing adverse effects, as measured using the Ketamine Side Effect Tool.
Timepoint [15] 370068 0
Days 0, 7, 114, 21, 28, 56, 182.
Secondary outcome [16] 370069 0
Exploratory outcome: To assess the safety of low-dose subcutaneous ketamine by analysing psychotomimetic effects, using the Brief Psychiatric Rating Scale and Clinician Administered Dissociative Symptoms Scale.
Timepoint [16] 370069 0
Treatment Days 0, 7, 14, 21.
Secondary outcome [17] 370070 0
Exploratory outcome: To assess the safety of low-dose subcutaneous ketamine by analysing abuse liability as assessed using the Alcohol, Smoking and Substance Involvement Screening Tool and the Brief Substance Craving Scale.
Timepoint [17] 370070 0
Week 4 (Day 28), Week 8 (Day 28) and Week 26 (Day 182) follow-ups.
Secondary outcome [18] 370071 0
Exploratory outcome: To investigate biomarkers of ketamine's effect using pre- and post-treatment assessment of magnetic resonance spectroscopy to examine brain spectra of glutamate, glutamine and glutathione.
Timepoint [18] 370071 0
Week 4 (Day 28) Follow-up.
Secondary outcome [19] 370072 0
Exploratory outcome: To investigate biomarkers of ketamine's effect using pre- and post-treatment assessment of functional magnetic resonance imaging tasks to identify baseline predictors of treatment response, and brain correlates of response.
Timepoint [19] 370072 0
Week 4 (Day 28) Follow-up
Secondary outcome [20] 370073 0
Exploratory outcome: To investigate biomarkers of ketamine's effect using pre- and post-treatment assessment of blood samples to conduct pharmacokinetic analysis of plasma concentrations of ketamine and its major active metabolites, and analyse biomarkers related to treatment response (e.g., brain derived neurotrophic factor)
Timepoint [20] 370073 0
Day 0 and Day 28.
Secondary outcome [21] 370074 0
Exploratory outcome: To investigate functional markers of ketamine's effect using pre- and post-treatment assessment of objective (actigraphy) and subjective (Pittsburgh Sleep Quality Index) measures of sleep to assess whether sleep is a mechanism underlying ketamine’s rapid anti-depressant effects, and whether sleep effects predict treatment response to ketamine.
Timepoint [21] 370074 0
Week 4 (Day 28) Follow up.
Secondary outcome [22] 370075 0
Exploratory outcome: To investigate functional markers of ketamine's effect using acute drug effects (assessed using the Hood Mysticism Scale and the Drug Effects Questionnaire) to assess whether such effects predict treatment response.
Timepoint [22] 370075 0
Treatment days 0, 7, 14 and 21.
Secondary outcome [23] 370076 0
Exploratory outcome: To assess whether early anti-depressant response to ketamine (measured by the MADRS at 24 hours after each treatment) is a potential predictor of sustained anti-depressant response (measured by the MADRS at weeks 4, 8 and 26).
Timepoint [23] 370076 0
Week 4 (Day 28), Week 8 (Day 56), and Week 26 (Day 182) Follow-ups.

Eligibility
Key inclusion criteria
• Age 16–25 years inclusive at the time of providing informed consent;
• Current MDD as assessed using the Structured Clinical Interview for DSM-5 (SCID-5);
• MADRS score greater than or equal to 22 – equivalent to moderate-to-severe depression – within 7 days (Day -7 to Day -1) of the first treatment visit;
• Treatment with either a stable dose of an antidepressant or no antidepressant medication for greater than or equal to 2 weeks;
• Ability to provide written informed consent (including both adequate intellectual capacity and fluency in the English language).
Minimum age
16 Years
Maximum age
25 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Severe disturbance such that the young person would be unable to comply with the requirements of informed consent or comply with the study protocol, as determined by the trial doctor;
• History of psychosis or bipolar disorder (assessed with SCID-5);
• Any unstable medical or neurologic condition, or medical or pharmaceutical contraindication to ketamine or midazolam use (as indicated in the Product Information forms for ketamine and midazolam);
• Any history of a ketamine use disorder of any severity, or presence of a substance use disorder of at least moderate severity (DSM-5) within the preceding 6 months, as determined by the trial doctor;
• Females who are pregnant or currently breastfeeding, or who are not using effective contraception.
• Participation in any other clinical intervention trial from SKY-D baseline to the Week 8 follow-up.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
This study uses a double blind design, such that allocation is concealed to the person who determines eligibility. Allocation will be determined using the online Research Project Management System (RPMS) that has been developed at Orygen, which conceals the allocation sequence.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation sequence will be developed by a statistician independent of the trial. Randomisation will be stratified by trial site and age (under 21 years, and 21 years and over). Random permutated blocks will be used.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The primary analyses will be based on the intention-to-treat (ITT) inclusion of all participants randomised. Wherever applicable we will use generalised linear mixed models to analyse both efficacy and safety outcomes, as these models have a number of features relevant to this study: (i) tolerance of missing data; (ii) allowance of both normally distributed outcomes (e.g., MADRS scores) and non-normal outcomes (e.g., binary measures such as remission) in the models; and (iii) incorporation of random effects to allow for inter-individual differences, especially for longitudinal data and site effects.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
20/05/2019
Actual
1/07/2019
Date of last participant enrolment
Anticipated
30/11/2023
Actual
11/09/2023
Date of last data collection
Anticipated
11/03/2024
Actual
Sample size
Target
140
Accrual to date
Final
110
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC

Funding & Sponsors
Funding source category [1] 302656 0
Government body
Name [1] 302656 0
National Health and Medical Research Council of Australia
Country [1] 302656 0
Australia
Primary sponsor type
Other
Name
Orygen, the National Centre of Excellence in Youth Mental Health
Address
35 Poplar Rd (Locked Bag 10)
Parkville VIC 3052
Country
Australia
Secondary sponsor category [1] 302576 0
None
Name [1] 302576 0
Address [1] 302576 0
Country [1] 302576 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 303278 0
Melbourne Health Human Research Ethics Committee
Ethics committee address [1] 303278 0
Ethics committee country [1] 303278 0
Australia
Date submitted for ethics approval [1] 303278 0
28/08/2018
Approval date [1] 303278 0
13/11/2018
Ethics approval number [1] 303278 0
HREC/42984/MH-2018

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 93110 0
Prof Christopher Davey
Address 93110 0
Level 1 North Block
Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Australia
Country 93110 0
Australia
Phone 93110 0
+61 3 8344 5509
Fax 93110 0
Email 93110 0
c.davey@unimelb.edu.au
Contact person for public queries
Name 93111 0
Christopher Davey
Address 93111 0
Level 1 North Block
Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Australia
Country 93111 0
Australia
Phone 93111 0
+61 3 8344 5509
Fax 93111 0
Email 93111 0
c.davey@unimelb.edu.au
Contact person for scientific queries
Name 93112 0
Christopher Davey
Address 93112 0
Level 1 North Block
Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Australia
Country 93112 0
Australia
Phone 93112 0
+61 3 8344 5509
Fax 93112 0
Email 93112 0
c.davey@unimelb.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All of the individual participant data collected during the trial, after deidentification.
When will data be available (start and end dates)?
Data will be available Immediately following publication, for an indefinite time
Available to whom?
Data will potentially be available to researchers from not-for profit organisations, commercial organisations or other based in any location. All data requests will be considered by the data custodian and the primary sponsor on a case-by-case basis. Requests must include a methodologically sound proposal. Specific conditions of use may apply and will be specified in a data sharing agreement (or similar) that the requester must agree to before access is granted. For further information, see Orygen data sharing policy
Available for what types of analyses?
To any type of analyses. Assessed on a case-by-case basis
How or where can data be obtained?
Access can be requested via the Health Data Australia catalogue (https://researchdata.edu.au/health). Search for the ACTRN number in the catalogue to find datasets associated with this trial.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
5340Study protocol    377513-(Uploaded-27-10-2023-12-49-23)-Study-related document.pdf
5341Statistical analysis plan  research@orygen.org.au
5342Informed consent form  research@orygen.org.au



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder.2023https://dx.doi.org/10.1186/s13063-023-07631-3
N.B. These documents automatically identified may not have been verified by the study sponsor.